403 related articles for article (PubMed ID: 21145405)
21. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia.
Trenado A; Charlotte F; Fisson S; Yagello M; Klatzmann D; Salomon BL; Cohen JL
J Clin Invest; 2003 Dec; 112(11):1688-96. PubMed ID: 14660744
[TBL] [Abstract][Full Text] [Related]
22. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
[TBL] [Abstract][Full Text] [Related]
23. Role of naturally arising regulatory T cells in hematopoietic cell transplantation.
Nguyen VH; Zeiser R; Negrin RS
Biol Blood Marrow Transplant; 2006 Oct; 12(10):995-1009. PubMed ID: 17084366
[TBL] [Abstract][Full Text] [Related]
24. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.
Yarkoni S; Prigozhina TB; Slavin S; Askenasy N
Biol Blood Marrow Transplant; 2012 Apr; 18(4):523-35. PubMed ID: 22227590
[TBL] [Abstract][Full Text] [Related]
25. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
[TBL] [Abstract][Full Text] [Related]
26. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
27. Induction of transplantation tolerance by allogeneic donor-derived CD4(+)CD25(+)Foxp3(+) regulatory T cells.
Velásquez-Lopera MM; Eaton VL; Lerret NM; Correa LA; Decresce RP; García LF; Jaramillo A
Transpl Immunol; 2008 May; 19(2):127-35. PubMed ID: 18503888
[TBL] [Abstract][Full Text] [Related]
28. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
29. Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.
Vogtenhuber C; Bucher C; Highfill SL; Koch LK; Goren E; Panoskaltsis-Mortari A; Taylor PA; Farrar MA; Blazar BR
Blood; 2010 Jul; 116(3):466-74. PubMed ID: 20442366
[TBL] [Abstract][Full Text] [Related]
30. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.
Li J; Heinrichs J; Haarberg K; Semple K; Veerapathran A; Liu C; Anasetti C; Yu XZ
J Immunol; 2015 Jul; 195(2):717-25. PubMed ID: 26048147
[TBL] [Abstract][Full Text] [Related]
31. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
32. Infusion of Lin- bone marrow cells results in multilineage macrochimerism and skin allograft tolerance in minimally conditioned recipient mice.
Anam K; Amare MF; Zins SR; Davis TA
Transpl Immunol; 2010 Oct; 24(1):69-75. PubMed ID: 20950686
[TBL] [Abstract][Full Text] [Related]
33. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
34. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
[TBL] [Abstract][Full Text] [Related]
35. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
Johnson BD; McCabe C; Hanke CA; Truitt RL
J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
[TBL] [Abstract][Full Text] [Related]
36. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
Xia G; Kovochich M; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
[TBL] [Abstract][Full Text] [Related]
37. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model.
Hasegawa H; Inoue A; Kohno M; Lei J; Miyazaki T; Yoshie O; Nose M; Yasukawa M
Gene Ther; 2008 Feb; 15(3):171-82. PubMed ID: 17989707
[TBL] [Abstract][Full Text] [Related]
39. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
Prigozhina TB; Elkin G; Khitrin S; Slavin S
Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
[TBL] [Abstract][Full Text] [Related]
40. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]